Novartis to co promote combination Lenvima (lenvatinib) with Afinitor (everolimus) for renal cell carcinoma in the US
Novartis Pharmaceuticals Corporation announced an agreement with Eisai Inc. to collaborate on commercial and certain medical affairs activities in the United States (US) to co-promote Lenvima (lenvatinib) capsules used in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
Everolimus is marketed by Novartis as Afinitor tablets. The collaboration follows the FDA approval last month of Lenvima in combination with everolimus for this indication, the only VEGF-mTOR inhibitor regimen approved in the US for patients with advanced RCC. Lenvima was granted Breakthrough Therapy designation by the FDA for this indication.
Under the terms of the collaboration agreement, Novartis and Eisai will promote the availability of this combination regimen to appropriate healthcare professionals nationwide, and participate in certain joint medical affairs activities to facilitate appropriate medical use of and medical education regarding the combination. Each company will continue to book sales of its respective product.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins